These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11110054)

  • 1. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.
    Chi KC; Wallis AE; Lee CH; De Menezes DL; Sartor J; Dragowska WH; Mayer LD
    Breast Cancer Res Treat; 2000 Oct; 63(3):199-212. PubMed ID: 11110054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE; Mayer LD
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE; Albritton KH; Bastar JD; Randall RL
    J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
    Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
    Lopes de Menezes DE; Hu Y; Mayer LD
    J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells.
    Simões-Wüst AP; Olie RA; Gautschi O; Leech SH; Häner R; Hall J; Fabbro D; Stahel RA; Zangemeister-Wittke U
    Int J Cancer; 2000 Aug; 87(4):582-90. PubMed ID: 10918201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.
    Anai S; Goodison S; Shiverick K; Hirao Y; Brown BD; Rosser CJ
    Mol Cancer Ther; 2007 Jan; 6(1):101-11. PubMed ID: 17237270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
    Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
    Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why G3139 works poorly in cancer trials but might work well against HIV.
    Parris GE
    Med Hypotheses; 2007; 69(3):537-40. PubMed ID: 17363184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
    Benimetskaya L; Lai JC; Khvorova A; Wu S; Hua E; Miller P; Zhang LM; Stein CA
    Clin Cancer Res; 2004 Dec; 10(24):8371-9. PubMed ID: 15623615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells.
    Nahta R; Yuan LX; Fiterman DJ; Zhang L; Symmans WF; Ueno NT; Esteva FJ
    Mol Cancer Ther; 2006 Jun; 5(6):1593-601. PubMed ID: 16818519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligodeoxynucleotide.
    Yang JH; Feng F; Qian H; Cheng H
    Breast; 2004 Jun; 13(3):227-31. PubMed ID: 15177426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).
    Raffo A; Lai JC; Stein CA; Miller P; Scaringe S; Khvorova A; Benimetskaya L
    Clin Cancer Res; 2004 May; 10(9):3195-206. PubMed ID: 15131061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
    van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
    Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.